The Expression of WTAP Gene in Acute Myeloid Leukemia and Its Clinical Significance.
10.19746/j.cnki.issn.1009-2137.2021.03.001
- Author:
Lu-Lu YANG
1
;
Ran-Ran ZHAO
1
;
Ruo-Yu JIANG
1
;
Hong LIU
1
;
Shi-Yuan ZHOU
1
;
Bin GU
1
;
Xiao-Jin WU
2
;
De-Pei WU
3
Author Information
1. National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou 215006, Jiangsu Province, China.
2. National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou 215006, Jiangsu Province, China,E-mail: wuxiaojin@suda.edu.cn.
3. National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou 215006, Jiangsu Province, China,E-mail: wudepei@medmail.com.cn.
- Publication Type:Journal Article
- MeSH:
Cell Cycle Proteins;
Humans;
Karyotype;
Leukemia, Myeloid, Acute/genetics*;
Mutation;
Prognosis;
RNA Splicing Factors;
Remission Induction;
fms-Like Tyrosine Kinase 3/genetics*
- From:
Journal of Experimental Hematology
2021;29(3):653-660
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the expression of WTAP gene in acute myeloid leukemia (AML) and its clinical significance.
METHODS:74 acute myeloid leukemia patients with non-M3 type and 19 normal donors were selected, and real-time quantitative polymerase chain reaction was used to detect the mRNA expression level of WTAP gene in their bone marrow cells. The relationship between the mRNA expression level of WTAP gene and the clinical characteristics was analyzed.
RESULTS:The relative mRNA expression of WTAP gene in the non-M3 AML group was significantly higher than that in the healthy control group, and the difference showed statistically significant (P<0.01). There showed no statistically significant difference in WTAP gene expression among each subtypes (all P>0.05) according to the classification of FAB. The mRNA expression level of WTAP gene in FLT3-ITD mutated AML patients was higher than that in FLT3-ITD unmutated group (P=0.016), and the mRNA expression level of WTAP gene in AML patients with CEBPα mutation was lower than that in CEBPα unmutated group (P=0.016). The expression level of WTAP mRNA was positively correlated with WT1 expression (r=0.6866, P<0.01). There was no relationship between WTAP mRNA expression level and other clinical parameters, such as age, gender, white blood cell count, hemoglobin level, platelet count, bone marrow original proportion of immature cells, chromosome karyotype, and NPM1, DNMT3A, ASXL1, NRAS, TET2 genes mutation status (P>0.05). The expression level of WTAP mRNA showed no obvious effect on the complete remission of patients after first treatment. The different expression level of WTAP gene at initial diagnosis showed also no effect on the overall survival time of patients.
CONCLUSION:The expression level of WTAP gene is increasing in new diagnosed non-M3 acute myeloid leukemia. There is a positive correlation between the expression level of WTAP gene and the expression level of WT1 fusion gene. WTAP mRNA always shows higher expression in patients with FLT3-ITD mutation than that in patients without FLT3-ITD mutation, and shows lower expression in patients with CEBPα mutation than that in unmutated group.
